Treats multiple myeloma. Sold as Xpovio. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Selinexor (sold as Xpovio), first approved Jul 3, 2019, with 3 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Xpovio | Part D | $107M | +9% | 1,168 |
| Imlunestrant/Abemaciclib/Selinexor in Ovarian and EndometrialLow Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer · Dana-Farber Cancer Institute | Phase 2 | Not yet recruiting | Sep 21, 2026 |
| A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCTAcute Myeloid Leukaemia (AML), MDS (Myelodysplastic Syndrome) · Liping Dou | Phase 1 / Phase 2 | Active, not recruiting | Aug 21, 2026 |
| Selinexor, Daratumumab, and Dexamethasone (XDd) for Light-Chain Cardiac AmyloidosisLight-chain Cardiac Amyloidosis · Beijing Anzhen Hospital | Phase 2 | Not yet recruiting | Aug 4, 2026 |
| New Genotype-guided Treatment in Newly Diagnosed PTCLPeripheral T-cell Lymphoma (PTCL) · Ruijin Hospital | Phase 1 / Phase 2 | Not yet recruiting | Jul 16, 2026 |
| Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaDiffuse Large B-Cell Lymphoma (DLBCL) · Second Affiliated Hospital, Zhejiang University, School of Medicine | — | Not yet recruiting | Jun 25, 2026 |
| The Efficacy and Safety of Selinisole Combined With Azacitidine and Venetoclax in the Treatment of Newly Diagnosed High-risk Myeloid Tumors With TP53 MutationsMyeloid Tumors · Bing Han | Not applicable | Not yet recruiting | Jun 8, 2026 |
| Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative NeoplasmsMyeloproliferative Neoplasms · Zhongshan Hospital (Xiamen), Fudan University | Phase 2 | Not yet recruiting | Jun 4, 2026 |
| A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003Relapsed or Refractory Multiple Myeloma · Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 | Recruiting | Jun 3, 2026 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jul 3, 2019 | XpovioNDA 212306 · New molecular entity | Karyopharm Theraps | 7 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA